Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hjalmar Steinhauer"'
Autor:
Reza Parwaresch, Joerg Hasford, Hanneke C. Kluin-Nelemans, Eva Hoster, Marc Boogaerts, Jean-Michel Boiron, Christian Gisselbrecht, Wolfgang Hiddemann, Vittorio Silingardi, Hjalmar Steinhauer, Georg Lenz, Martin Dreyling, Rudolf Schmits, Ali Aldaoud, Bernd Metzner, Achiel Van Hoof, Lorenz Truemper, Michael Unterhalt, Marcel Reiser
Publikováno v:
Blood, 105(7), 2677-2684. AMER SOC HEMATOLOGY
Mantle-cell lymphoma (MCL) is characterized by poor prognosis with a median survival of only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a randomized trial comparing consolidation with myeloablative radiochemotherapy
Autor:
Reza Parwaresch, Joerg Hasford, Wolfgang Hiddemann, Georg Lenz, Eva Hoster, Hjalmar Steinhauer, Michael Unterhalt, Andreas Neubauer, Bernd Metzner, Ali Aldaoud, Hannes Wandt, Martin Dreyling, Bernhard Wörmann, Sonja Martin, Else Heidemann, Hartmut Eimermacher, Ulrich Dührsen
Publikováno v:
Journal of Clinical Oncology. 23:1984-1992
Purpose Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG)
Autor:
Eva Lengfelder, Carsten Zwick, Viola Poeschel, Niels Murawski, Norbert Schmitz, Samira Zeynalova, Christina Limmroth, Marcel Reiser, Carsten Mueller, Hjalmar Steinhauer, Gerhard Held, Michael Pfreundschuh
Publikováno v:
Journal of Clinical Oncology. 30:8024-8024
8024 Background: Gender and weight independently influence R clearance and R serum elimination half life (Mueller et al., Blood 2012). To investigate whether the differences in R pharmacokinetics translate into different outcomes, we analyzed elderly
Autor:
Michael Pfreundschuh, Bernd Metzner, Samira Zeynalova, Marion Hoffmann, Michael R. Clemens, M. Loeffler, Marita Ziepert, Christine Nickenig, N. Schmitz, Viola Poeschel, Hjalmar Steinhauer, Eva Lengfelder, A. D. Ho, R. H. Mertelsmann, Lorenz Truemper, H. Mergenthaler
Publikováno v:
Journal of Clinical Oncology. 29:8029-8029
8029 Background: Interval reduction from 3 (CHOP-21) to 2 wks (CHOP-14) and the addition of R to CHOP-21 (R-CHOP-21) improved outcome in elderly pts with DLBCL to a similar extent compared to CHOP-21. Methods: In the RICOVER-60 trial, elderly pts.(61
Autor:
Johanna Kluin-Nelemans, Marcel Reiser, Martin Dreyling, Vittorio Silingardi, Jean-Michel Boiron, Eva Hoster, Michael Unterhalt, Hjalmar Steinhauer, Marc Boogaerts, Christian Gisselbrecht, Wolfgang Hiddemann, Bernd Metzner, Achiel Van Hoof, Michael Pfreundschuh, Lorenz Truemper
Publikováno v:
Blood. 112:769-769
Background: Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma with an especially poor prognosis and a median survival of only 3–4 years. Methods: In 1996, the European MCL Network initiated a randomized trial to improve the dis
Autor:
Wolfgang Hiddemann, Eva Hoster, Ali Aldaoud, Michael Unterhalt, Bernd Metzner, Martin Dreyling, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Bernhard Wörmann, Sonja Martin, Else Heidemann, Hartmut Eimermacher, Ulrich Dührsen
Publikováno v:
Blood. 112:3049-3049
Background: The addition of rituximab to chemotherapy (R-CHOP) has been shown to improve response rates in mantle cell lymphoma (MCL), but prolongation of response duration or overall survival was not observed (Lenz et al., JCO 2005). In a similar ra
Autor:
Astrid Franke, Christina Nickenig, Manfred Hensel, Bernd Metzner, Markus Loeffler, N. Schmitz, Marcel Reiser, Viola Poeschel, Hjalmar Steinhauer, Michael Pfreundschuh, Monika Engelhardt, Samira Zeynalova, Marita Kloess, Ruediger Liersch, Eva Lengfelder, Joerg Schubert, Ulrich Duehrsen, Michael R. Clemens, Lorenz Truemper, Hans-Guenther Mergenthaler, Maike de Wit, Leopold Balleisen
Publikováno v:
Blood. 108:205-205
Interval reduction from 3 (CHOP-21) to 2 weeks (CHOP-14; Pfreundschuh et al., Blood, 2004) and the addition of rituximab to CHOP-21 (R-CHOP-21; Coiffier et al., NEJM, 2002) improved outcome in elderly patients with DLBCL to a similar extent compared
Autor:
Michael Wenger, Marcel Reiser, Astrid Franke, Marita Kloess, Hjalmar Steinhauer, N. Schmitz, Eva Lengfelder, Michael Pfreundschuh, M. Loeffler, Michael R. Clemens, J. Schubert
Publikováno v:
Journal of Clinical Oncology. 24:7536-7536
7536 Background: The addition of rituximab (R) to 3-weekly CHOP-21 improved overall results in elderly patients with DLBCL, but was more effective in good-prognosis (g-p: IPI = 1,2) than poor-prognosis (p-p: IPI = 3,4,5) patients (JCO 23:4117, 2005).